Polymers for Hyperuricemia Treatment Granted to Waterstone
Summary
The USPTO granted patent US12605401B2 to Waterstone Pharmaceuticals (Wuhan) Co., Ltd. covering polymers and compositions for binding uric acid and treating hyperuricemia, gout, and related diseases. The patent, with 20 claims, was filed on May 18, 2022 under Application No. 17747006 and lists eight inventors.
What changed
The USPTO issued patent US12605401B2 to Waterstone Pharmaceuticals (Wuhan) Co., Ltd. for small molecule compounds, polymers, and compositions effective for binding uric acid or its precursors, and for treating hyperuricemia, gout, and associated diseases. The patent covers eight named inventors and provides 20 claims.
For pharmaceutical companies developing treatments for hyperuricemia or gout, this grant establishes Waterstone's intellectual property position in polymer-based uric acid binding technology. Competitors pursuing similar polymer approaches should review this patent landscape to assess freedom-to-operate considerations.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Polymers, compositions and methods for treating hyperuricemia
Grant US12605401B2 Kind: B2 Apr 21, 2026
Assignee
WATERSTONE PHARMACEUTICALS (WUHAN) CO., LTD.
Inventors
Youcheng Zhou, Tongtong Li, Minglong Hu, Yan Li, Kang Bie, Ying Liang, Jian Cui, Faming Zhang
Abstract
The disclosure provides small molecule compounds, polymers, and compositions thereof, as well as methods for preparing such polymers and compositions. Also provided is a method of using the polymers or compositions thereof for binding uric acid or precursor thereof, and/or for treating hyperuricemia, gout, and/or diseases caused by hyperuricemia.
CPC Classifications
A61K 31/787 A61P 19/06 C08F 279/00
Filing Date
2022-05-18
Application No.
17747006
Claims
20
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.